A Maryland-based biotechnology company announced the initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373, the Company’s COVID-19 vaccine candidate.
Novavax, Inc. stated on December 28, 2020; the Phase 3 trial has begun enrolling adult volunteers into the randomized, placebo-controlled trial, which intends to enroll approximately 30,000 people at about 115 sites.
5th COVID-19 Vaccine Launches Phase 3 Study
Male Sex Is Risk Factor for Increased Mortality in COVID-19
Diabetes with chronic complications, hypertension with chronic complications, obesity show age-dependent effects
SARS-CoV-2 Infection Rate Low in Patients Receiving Antitumor Therapy
Less than 1 percent of patients receiving antitumor treatment between Jan. 15 and May 4, 2020, developed COVID-19
Early Tracheostomy May Be Considered in Severe COVID-19
Findings challenge recommendations to delay or avoid tracheostomy in this patient population
LY-CoV555 Not Efficacious for Hospitalized Patients With COVID-19
Enrollment stopped for futility based on no difference in pulmonary function on day 5 compared with placebo
HD Live! Takes a Look Back at Pandemic’s Progression
David Shulkin, M.D., and Joel Zivot, M.D., discuss handling of pandemic, overcoming vaccine hesitancy
CDC: Travelers From the U.K. Must Have Negative COVID-19 Test
If a traveler opts not to take a test, the airline must deny boarding the passenger
WHO Calls for New Measures to Identify COVID-19 Variants
New variants found in Britain and South Africa appear to be more contagious and have triggered new travel restrictions